Protalix Biotherapeutics Inc
F:PBDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Protalix Biotherapeutics Inc
F:PBDA
|
US |
|
Sofina SA
XBRU:SOF
|
BE |
|
S
|
Surteco Group SE
XMUN:SUR
|
DE |
Intrinsic Value
Is PBDA undervalued or overvalued?
See the intrinsic value estimate for Protalix Biotherapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Protalix Biotherapeutics Does
Protalix Biotherapeutics makes biologic medicines, especially replacement enzymes for rare genetic diseases. Its core technology grows therapeutic proteins in plant cells, not in the usual animal-cell factories, and the company turns that into finished drugs or drug candidates for rare-disease patients. Its best-known products are treatments for conditions such as Gaucher disease and Fabry disease, which are sold through partners and specialty drug channels.
- Headquarters
- United States of America US
- Employees
- 226
- IPO date
- Sep 6, 2010
Revenue & Expenses Breakdown
Protalix Biotherapeutics Inc
Earnings Waterfall
Protalix Biotherapeutics Inc
The intrinsic value for Protalix Biotherapeutics Inc (PBDA) under the Base Case is hidden EUR.
Compared with the current market price of 2.27 EUR, the stock appears hidden.